US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

5.80

+0.44008.21%

Post-market: 5.820.0199+0.34%19:59 EDT

Volume:2.61M

Turnover:14.81M

Market Cap:446.68M

PE:-4.33

High:5.90

Open:5.50

Low:5.25

Close:5.36

Loading ...

Overview Company News Filings

Shares of Viking Therapeutics up 9.3%, Structure Therapeutics up 3.4%, Altimmune up 1.7% Premarket

THOMSON REUTERS

Altimmune to Join Nasdaq Biotechnology Index

MT Newswires Live

BUZZ-Altimmune up on addition to Nasdaq Biotech index

Altimmune to be added to the Nasdaq Biotechnology Index

Altimmune Added to Nasdaq Biotechnology Index

THOMSON REUTERS

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

ALT Resources PLC Sets Date for Annual General Meeting

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

Zacks Small Cap Research

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Stock Track | Altimmune Soars 6.69% After-hours on Positive Pembrolizumab Subcutaneous Formulation Phase 3 Data

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALT/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALT\",,,,,undefined,":{"symbol":"ALT","market":"US","secType":"STK","nameCN":"Altimmune, Inc.","latestPrice":5.8,"timestamp":1746734400000,"preClose":5.36,"halted":0,"volume":2611027,"hourTrading":{"tag":"盘后","latestPrice":5.8199,"preClose":5.8,"latestTime":"19:59 EDT","volume":55489,"amount":321828.0731,"timestamp":1746748753803},"delay":0,"floatShares":76335159,"shares":77013658,"eps":-1.338795,"marketStatus":"Closed","change":0.44,"latestTime":"05-08 16:00:00 EDT","open":5.5,"high":5.9,"low":5.25,"amount":14813632.963203,"amplitude":0.121269,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.338795,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746777600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.36,"preHourTrading":{"tag":"盘前","latestPrice":5.56,"preClose":5.36,"latestTime":"09:29 EDT","volume":44099,"amount":242688.92422500002,"timestamp":1746710988510},"postHourTrading":{"tag":"盘后","latestPrice":5.8199,"preClose":5.8,"latestTime":"19:59 EDT","volume":55489,"amount":321828.0731,"timestamp":1746748753803},"volumeRatio":0.92604,"impliedVol":1.8464,"impliedVolPercentile":0.988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALT\",,,,,undefined,":{"symbol":"ALT","floatShares":76335159,"roa":"-36.85%","roe":"-59.86%","lyrEps":-1.338795,"volumeRatio":0.92604,"shares":77013658,"dividePrice":0,"high":5.9,"amplitude":0.121269,"preClose":5.36,"low":5.25,"week52Low":3.553,"pbRate":"3.62","psRate":"22333.96","week52High":11.16,"institutionHeld":0.7725,"latestPrice":5.8,"eps":-1.338795,"divideRate":0,"volume":2611027,"delay":0,"ttmEps":-1.338795,"open":5.5,"prevYearClose":7.21,"prevWeekClose":5.77,"prevMonthClose":5.25,"prevQuarterClose":5,"fiveDayClose":5.17,"twentyDayClose":4.23,"sixtyDayClose":6.29,"earningDate":1747065600000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALT\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492415454","title":"Shares of Viking Therapeutics up 9.3%, Structure Therapeutics up 3.4%, Altimmune up 1.7% Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2492415454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492415454?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:03","pubTimestamp":1734692639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nFWN3NL0CN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1127390331.HKD","LU2237443895.HKD","LU2106854487.HKD","LU1974910355.USD","LU1064131342.USD","GPCR","BK4599","IE00B1BXHZ80.USD","ALT","SGXZ57979304.SGD","LU0256863902.USD","LU1868836591.USD","LU2089984988.USD","LU2602419157.SGD","LU0820561818.USD","SG9999015945.SGD","BK4534","LLY","IE00B4R5TH58.HKD","SG9999015952.SGD","BK4007","LU1061106388.HKD","LU0079474960.USD","LU1291159041.SGD","SG9999015978.USD","LU0109391861.USD","LU1069344957.HKD","LU0708995401.HKD","LU1804176565.USD","LU2237443382.USD","SG9999018857.SGD","LU1878469433.USD","LU1868836914.USD","LU2265009873.SGD","LU0466842654.USD","IE00BJT1NW94.SGD","LU0471298694.HKD","LU2461242641.AUD","LU0882574055.USD","LU2324357040.USD","IE00BJLML261.HKD","LU0256863811.USD","VKTX","LU2211815571.USD","LU2023250504.SGD","LU1093756168.USD","LU0471298777.SGD","LU2237443549.SGD","IE00BJJMRZ35.SGD","LU2491049909.HKD"],"gpt_icon":0},{"id":"2492170687","title":"Altimmune to Join Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492170687","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492170687?lang=en_us&edition=fundamental","pubTime":"2024-12-19 23:45","pubTimestamp":1734623140,"startTime":"0","endTime":"0","summary":"Altimmune  said Thursday it will be added to the Nasdaq Biotechnology Index before trading begins on Dec. 23.The company said the index is designed to track the performance of biotechnology and pharmaceutical companies listed on the Nasdaq stock exchange and serves as the basis for the iShares Nasdaq Biotechnology Index Fund.Shares of the company were up 4.6% in recent trading.Price: 8.26, Change: +0.36, Percent Change: +4.56","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1878469433.USD","NDAQ","USAW.SI","LU2095319765.USD","IE00BGHQF748.EUR","QLD","TQQQ","ALT","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","BK4112","PSQ","NVIW.SI","BK7007","IE00B3QW5Z07.USD","TSYW.SI","QID","BK4585","USJW.SI","LU2210149790.SGD","ALT.AU","NQmain","BK4599","SQQQ","BK4588","LU2210150020.SGD","MNQmain",".IXIC"],"gpt_icon":1},{"id":"2492736441","title":"BUZZ-Altimmune up on addition to Nasdaq Biotech index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492736441","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492736441?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:53","pubTimestamp":1734616422,"startTime":"0","endTime":"0","summary":"BUZZ-Altimmune up on addition to Nasdaq Biotech index** Drug developer Altimmune's ALT.O shares rise ~2% to $8.05 premarket** Company says its shares will be added to Nasdaq Biotechnology index .NBI before market opens on Dec. 23** Company currently testing pemvidutide for treatment of obesity and metabolic dysfunction-associated steatohepatitis ** Avg rating of brokerages covering Altimmune stock is \"buy\"; median PT $24 - LSEG** As of last close, company's shares have fallen 29.8% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK13R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4599","ALT","BK4139"],"gpt_icon":0},{"id":"2492122232","title":"Altimmune to be added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492122232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492122232?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:41","pubTimestamp":1734612077,"startTime":"0","endTime":"0","summary":"Altimmune (ALT) will be added to the Nasdaq Biotechnology Index (NBI) effective prior to the market open on Monday, December 23, 2024. Published fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/altimmune-to-be-added-to-the-nasdaq-biotechnology-index?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/altimmune-to-be-added-to-the-nasdaq-biotechnology-index?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALT","PSQ","TQQQ","LU2210150020.SGD","BK4585","IE00B3QW5Z07.USD","QQQ","QID","IE00BGHQF748.EUR","MNQmain","LU2095319765.USD","LU1878469433.USD","QLD","SQQQ","BK4599","NQmain","NDAQ","USJW.SI","USAW.SI","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NVIW.SI","BK4588","IE00BKPKM429.USD","TSYW.SI","BK4112",".IXIC"],"gpt_icon":0},{"id":"2492161124","title":"Altimmune Added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492161124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492161124?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:30","pubTimestamp":1734611400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUAC1RS0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALT","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","BK4139","LU2095319765.USD","LU1878469433.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","BK4599","BK4588","NDAQ"],"gpt_icon":0},{"id":"2492012492","title":"Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI","url":"https://stock-news.laohu8.com/highlight/detail?id=2492012492","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492012492?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:30","pubTimestamp":1734611400,"startTime":"0","endTime":"0","summary":"Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities. Completed additional private placement with Gilead for purchase of remaining equity investment in connection with XTX301 partnership. WALTHAM, Mass., Dec. 19, 2024  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present initial data from its ongoing Phase 2 trial for vilastobart , a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab  in patients with metastatic microsatellite stable colorectal cancer  at the ASCO Gastrointestinal  Cancers Symposium in San Francisco, California from January 23-25, 2025. In addition, today the company announced preliminary data from Phase 1 dose escalation for XTX301, an investiga","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/w3j6s6GyGXevQnSvYrKEMg--~B/aD0yODk7dz00NjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/790a3773663b9c214f4e9c03501ad13e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/w3j6s6GyGXevQnSvYrKEMg--~B/aD0yODk7dz00NjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/790a3773663b9c214f4e9c03501ad13e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xilio-therapeutics-present-initial-phase-123000443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4509","BK4139","BK4531","LU0359201612.USD","BK4548","BK4565","BK4552","IE00B12V2V27.USD","IE00BYTNYN87.SGD","BK4599","LU0359202008.SGD","BK4108","SG9999011746.SGD","LU2039709279.SGD","BK4526","XLO","BK4535","BK4571","LENZ","BK4563","LU1023057109.AUD","ALT","01698","LU1878469433.USD","TME","IE00BYQNZ168.SGD","AST"],"gpt_icon":0},{"id":"2492183515","title":"MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183515","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183515?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526860,"startTime":"0","endTime":"0","summary":"DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering Effect. Patients Treated with DA-1241 100mg Achieved Statistically Significant Reduction in ALT Levels at Weeks 4 and 8, and a Near Statistically Significant Reduction at Week 16. DA-1241 100mg Demonstrated Statistically Significant Improvements in CAP Score at Week 16. Awaiting Data on Other Exploratory Endpoints Including MRI-PDFF. Additional Findings to be Submitted for Upcoming Scientific Conferences. * Confidence interval excludes 0, suggesting a statistically meaningful difference. p < 0.05 vs. placebo. Proportion of Subjects with Normalized ALT <30 IU/L at Week 16. LS Mean CAP, VCTE, FAST score Changes from Baseline at Week 16","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-130100214.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-130100214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4567","OXM","BK4104","IE00BYQQ9H92.USD","FAST","ALT","MTVA","BK4139","IE00BFXG0V08.USD","BK4599","BK4585","AST","GGT","IE00B5TLWC47.USD","LU1878469433.USD","BK4588","BK4202"],"gpt_icon":0},{"id":"2492960667","title":"ALT Resources PLC Sets Date for Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2492960667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492960667?lang=en_us&edition=fundamental","pubTime":"2024-12-18 00:37","pubTimestamp":1734453433,"startTime":"0","endTime":"0","summary":"ACP Energy PLC ( ($GB:ALTR) ) just unveiled an update. ALT Resources PLC has announced its upcoming Annual General Meeting scheduled for January 10...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alt-resources-plc-sets-date-for-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alt-resources-plc-sets-date-for-annual-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4599","LU1878469433.USD","ALT"],"gpt_icon":0},{"id":"2492959531","title":"Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959531","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959531?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:30","pubTimestamp":1734435000,"startTime":"0","endTime":"0","summary":"In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998078/0/en/Affimed-Reports-Positive-Clinical-Update-on-AFM24-Atezolizumab-Combination-Therapy-in-Non-Small-Cell-Lung-Cancer-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4161","PFS","BK4599","BK4213","AE","PR","BK4138","LU1878469433.USD","BK4195","ALT","BK4139","CR","BK4211","OS","BK4097","AST","LU0053666078.USD","FAS","L","BK4585","PPS","BK4107"],"gpt_icon":0},{"id":"2491214753","title":"Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2491214753","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491214753?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:37","pubTimestamp":1734089820,"startTime":"0","endTime":"0","summary":"– Recommendation Based on the RESPONSE Study Which Demonstrated ALP Normalization in 25% of Participants at 12 Months and Statistically Significant Reduction of Pruritus Versus Placebo –。The positive opinion was supported primarily by data from the pivotal placebo-controlled Phase 3 RESPONSE study. In the study, 62% of participants taking seladelpar achieved the primary endpoint of composite biochemical response at month 12 compared with 20% of participants taking placebo. Treatment with seladelpar led to normalization of ALP values in 25% of trial participants at month 12. This change was not seen in any trial participants receiving placebo. ALP is a cholestatic marker that is a predictor of risk for liver transplant and death. Change from baseline pruritus score at month 6 was a key s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pvxf9aCo6mke7xm8sJZyWg--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/86a7735b21854a533ac901b334cc91fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pvxf9aCo6mke7xm8sJZyWg--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/86a7735b21854a533ac901b334cc91fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-seladelpar-receives-positive-chmp-113700996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4550","LU0109394709.USD","UK","IE00B3T34201.USD","LU1066053197.SGD","BK4205","IE0002270589.USD","GGT","LU1839511570.USD","CHMP","BK4585","LU2468319806.SGD","LU0058720904.USD","LU0289739699.SGD","BK4528","IE00B19Z3B42.SGD","BK4599","BK4588","LU0234570918.USD","BK4233","LU0320765992.SGD","IE00BKVL7J92.USD","BK4578","BK4568","LU1585245621.USD","IE00BSNM7G36.USD","LU1878469433.USD","PBC","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","ALT","BK4566","LU2087621335.USD","LU1066051498.USD","LU1571399168.USD","BK4139","BK4583","BK4532","GILD","LU0889565916.HKD","IE00B7SZLL34.SGD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2491327214","title":"Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2491327214","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491327214?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:36","pubTimestamp":1734089760,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., December 13, 2024----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending the approval of RYTELO  for the treatment of adult patients with transfusion-dependent  anemia due to very low, low or intermediate risk myelodysplastic syndromes  without an isolated deletion 5q cytogenetic  abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The European Commission , which has the authority to approve medicines in the European Union , will review the CHMP’s recommendation and is expected to make a final decision on the marketing authorization application  in the following months.Lower-risk myelodysplastic syndromes  is a blood cancer that often progresses to require increasingly intensified manageme","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3xXvPBJ2NJ_uZgG.c_zzOQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3912c5832ea4ed32855cb10e0d53a4b2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3xXvPBJ2NJ_uZgG.c_zzOQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3912c5832ea4ed32855cb10e0d53a4b2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-announces-positive-chmp-opinion-113600100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","LU1878469433.USD","EC","CHMP","ALT","GERN","BK4139","BK4201","TD","BK4599","BK4585","AST","BK4566","BK4207","MAA","BK4215","BK4156","BK4588"],"gpt_icon":0},{"id":"2491354421","title":"Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2491354421","media":"Business Wire","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491354421?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":"– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs –。SAN FRANCISCO, December 12, 2024----Vir Biotechnology, Inc.  today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration  Breakthrough Therapy designation and European Medicines Agency  Priority Medicines  designation for the treatment of chronic hepatitis delta . The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AASLD The Liver Meeting in San Diego, U.S. Vir Biotechnology’s Phase 3 ECLIPSE registrational program evaluating tobevibart and elebsiran in CHD will commence in the first half of 2025.SOLSTICE is a Phase 2 study to evaluate the safety, tolerability, and efficacy of tobevibart,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-fda-breakthrough-210500608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHD","ALT","BK4568","LU1878469433.USD","BK4139","HDV","BK4599","BK4585","BK4539","BK4535","BK4018","BK4079","BK4588","COMP","VIR","BK4504"],"gpt_icon":0},{"id":"2490033037","title":"Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2490033037","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490033037?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:02","pubTimestamp":1733763720,"startTime":"0","endTime":"0","summary":"R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients. SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initialdata from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome . The data is beingpresented today by Dr. Guillermo Garcia-Manero  at the 66th American Society of Hematology  Annual Meeting and Exposition being held December 7-10, in San Diego, California and virtually.Rigel's open-label, Phase 1b study of R289 is enrolling patients with lower-risk MDS who are R/R to prior therapies . The primary objective of the study is to assess the safety and tolerability of R289 with secondary objectives to assess pre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/y.2KhNmww8BW2625tcZbsw--~B/aD0yMTY7dz0zNjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/y.2KhNmww8BW2625tcZbsw--~B/aD0yMTY7dz0zNjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rigel-highlights-initial-data-ongoing-170200978.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rigel-highlights-initial-data-ongoing-170200978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RBC","BK4161","BK4109","LU2463526074.USD","ALT","BK4166","BK4503","ASH","BK4599","LU1878469433.USD","LU2065731478.USD","RIGL","BK4563","IE00BLDYK493.USD","QD","IE00B64QTZ34.USD","BK4139","AST"],"gpt_icon":0},{"id":"2489222687","title":"BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489222687","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489222687?lang=en_us&edition=fundamental","pubTime":"2024-12-07 23:00","pubTimestamp":1733583600,"startTime":"0","endTime":"0","summary":"Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%. THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen  today announcednew data demonstrating that adding BLINCYTO  to chemotherapy significantly improves disease-free survival  in newly diagnosed pediatric patients with National Cancer Institute  standard risk  B-cell acute lymphoblastic leukemia  of average or higher risk of relapse. The data are from a Phase 3 study  conducted by the Children's Oncology Group. The results were simultaneously publishedin the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8, at 2 p.m. PT at the 66th American Society of Hematology  Annual Meeting & Exposition in San Diego.The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","ALT","IE00B19Z3581.USD","IE00BJJMRZ35.SGD","LU1059921491.USD","LU1571399168.USD","AMGN","BK4166","LU1165135440.EUR","LU0985320562.USD","IE00B19Z4B17.USD","IE00BFTCPJ56.SGD","CLS","CELL","LU0122379950.USD","CI","IE00B19Z3B42.SGD","NCI","BK4135","CNS","LU0106831901.USD","LU1861220207.SGD","ALL","LU2125910500.SGD","HR","LU1261432733.SGD","AST","CRS","TLS","DFS","IE0002141913.USD","LU1620156130.USD","LU1596574779.USD","LU1861217088.USD","ASH","MAS","LU0170899867.USD","SR","IE0031619046.USD","BK4156","LU1023059063.AUD","BK4196","BK4139","BK4533","BK4097","IE00B7SZL793.SGD","BK4588","LU2360107671.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2488923448","title":"MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923448","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923448?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:33","pubTimestamp":1733225580,"startTime":"0","endTime":"0","summary":"On November 18, 2024, NeuroBo Pharmaceuticals, Inc.  announced a strategic realignment ahead of upcoming clinical milestones along with a corporate name change to MetaVia Inc. . The change went into effect on November 29, 2024. We are republishing the latest research report under the MTVA ticker.MetaVia Inc. is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis . DA-1241 is a novel chemical entity that selectively activates GPR119, stimulates the secretion of insulin and incretin hormones such as glucagon-like peptide-1 , reduces plasma glucose levels without causing hypoglycemia, and lowers plasma lipid levels of both triglycerides and cholesterol.MAD Part 2 Results from Phase 1 Trial of DA-1726 Expected in 1Q25. The multiple ascending dose  Part 2 of the trial is ongoing, with the first patient enrolled in June 2024. A total of 36 individuals are expected to be enrolled in Part 2 of the trial in a 6:3 ratio across four dosing cohorts. Each particip","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6BnuZucQR4TI36e.yZdpVQ--~B/aD04NTY7dz0xMzc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/daa58845a8f57cfe3cbb544b5bfe2eda","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6BnuZucQR4TI36e.yZdpVQ--~B/aD04NTY7dz0xMzc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/daa58845a8f57cfe3cbb544b5bfe2eda"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-neurobo-becomes-metavia-topline-113300772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4218","BK4139","BK4599","MTVA","BK4181","PK","LU1878469433.USD"],"gpt_icon":0},{"id":"2488637675","title":"Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2488637675","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488637675?lang=en_us&edition=fundamental","pubTime":"2024-12-02 20:30","pubTimestamp":1733142600,"startTime":"0","endTime":"0","summary":"Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept for RMC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/02/2989693/0/en/Revolution-Medicines-Provides-Clinical-Updates-from-its-RAS-ON-Inhibitor-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","LU1548497426.USD","CRC","LU1854104046.USD","IE00B19Z3B42.SGD","BK4213","BK4141","BK4585","LU1059921491.USD","LU1720051017.SGD","MDCO","IE00BD6J9T35.USD","LU0058720904.USD","AST","LU1861215975.USD","BK4590","IE00B19Z3581.USD","BK4599","NE","LU2357305700.SGD","IE00BSNM7G36.USD","LU1854103824.USD","LU1861220033.SGD","IE0002270589.USD","BK4092","BK4563","ALT","BK4588","LU0456854461.SGD","LU0266512127.USD","CI","LU2298322129.HKD","BK4166","ET","LU1720051108.HKD","BK4196","QD","LU1878469433.USD","BK4139","LU1861219969.SGD","LU0868494617.USD","LU0124384867.USD","IE00BZ199S13.USD","ON","LU0724618433.USD","LU1978683503.SGD","BK4581","BK4503","LU0289739699.SGD","LU1861214812.USD"],"gpt_icon":0},{"id":"1194869450","title":"Stock Track | Altimmune Soars 6.69% After-hours on Positive Pembrolizumab Subcutaneous Formulation Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1194869450","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194869450?lang=en_us&edition=fundamental","pubTime":"2024-11-20 07:12","pubTimestamp":1732057967,"startTime":"0","endTime":"0","summary":"Altimmune, Inc.  shares surged 6.69% in after-hours trading on Tuesday, following positive topline results from Merck's Phase 3 MK-3475A-D77 trial evaluating the subcutaneous administration of pembrolizumab  together with Altimmune's berahyaluronidase alfa  in combination with chemotherapy for first-line treatment of metastatic non-small cell lung cancer .The trial met its dual primary pharmacokinetic endpoints, demonstrating non-inferior exposure of the subcutaneous pembrolizumab formulation co","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Altimmune Soars 6.69% After-hours on Positive Pembrolizumab Subcutaneous Formulation Phase 3 Data","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALT"],"gpt_icon":0},{"id":"2484956973","title":"Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956973","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956973?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982500,"startTime":"0","endTime":"0","summary":"– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –。– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –。– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –。– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –。These data were presented in an oral session at the American Association for the Study of Liver Diseases  The Liver Meeting, in San Diego, CA. Based on these results, and following a recent meeting with the FDA, Vir Biotechnology plans to initiate the Phase 3 registrational ECLIPSE program in the first half of 2025 to further evaluate the combination of tobevibart and elebsiran for the treatment of CHD.Primary Endpoint Analysis from the Phase 2 SOLSTICE Tria","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-presents-positive-chronic-021500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4585","COMP","BK4568","BK4079","VIR","CHD","BK4539","BK4139","BK4505","HDV","BK4018","LU1878469433.USD","BK4535","RNA","BK4588","BK4504"],"gpt_icon":0},{"id":"2484987837","title":"Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987837","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987837?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need –。– Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting –。SAN FRANCISCO, November 18, 2024----Vir Biotechnology, Inc.  today announced that the European Medicines Agency  Committee for Orphan Medicinal Products , has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta . This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference call is scheduled for November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET.In June 2024, the U.S. Food and Drug Adm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-positive-opinion-210500380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4079","BK4535","ALT","BK4539","MDCO","VIR","BK4018","BK4504","BK4568","HDV","BK4585","COMP","BK4588","BK4139","LU1878469433.USD","CHD"],"gpt_icon":0},{"id":"2484690173","title":"Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2484690173","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484690173?lang=en_us&edition=fundamental","pubTime":"2024-11-18 14:00","pubTimestamp":1731909600,"startTime":"0","endTime":"0","summary":"Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024. “We know from our work with patient communities that receiving a diagnosis of PFIC and ALGS can be overwhelming in a patient or caregivers’ life. Disease symptoms like severe itch can have an impact on the whole family,” said Sandra Silvestri, EVP Chief Medical Officer, Ipsen. “Data suggesting Bylvay-treated patients experienced sustained efficacy, and which support the safety and tolerability profile seen in previous clinical trials, are important. Ipsen is committed to being the leader across rare cholestatic liver diseases and we are just getting started.”Beyond the clinically meaningful and sustained improvements seen in pruritus and sBA levels, height, weight and sleep increases were reported at 72 weeks in Bylvay-treated patients. Most adverse events in Bylvay-treated patients over the duration of the stu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bylvay-odevixibat-data-shows-sustained-060000611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IPSEY","BK4079","BK4233","BK4532","AST","BK4213","IBAT","LB","FSV","BK4007","LU1878469433.USD","ALT","BK4505","BK4139","IPSEF","ALGS"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":124,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALT\",params:#limit:5,,,undefined,":[{"date":"2025-05-13","symbol":"ALT","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.36,"defaultRemindTime":1747123200000,"name":null,"time":"Pre-Market","dateTimestamp":1747108800000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"ALT","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-0.33},{"market":"US","date":"2024-11-12","symbol":"ALT","fiscalQuarterEnding":"2024/09","expectedEps":-0.36,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2024-08-08","symbol":"ALT","fiscalQuarterEnding":"2024/06","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2024-05-09","symbol":"ALT","fiscalQuarterEnding":"2024/03","expectedEps":-0.36,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.625,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1740715200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALT","date":"2025-05-07","current":-4.07514,"percent":0.740861,"low":-46.273572,"twenty":-9.229315,"median":-5.62647,"eighty":-3.29177,"high":-1.406077,"avg":-6.787836,"sd":5.450581,"marketCap":387378699},"quantilePoints":[{"date":"2020-05-08","current":-2.292473,"twenty":-1.256747,"median":-0.842537,"eighty":-0.527524,"marketCap":47041841},{"date":"2020-05-15","current":-3.074859,"twenty":-1.270658,"median":-0.844262,"eighty":-0.532381,"marketCap":68595403},{"date":"2020-05-22","current":-4.770149,"twenty":-1.345551,"median":-0.844264,"eighty":-0.535619,"marketCap":106414744},{"date":"2020-05-29","current":-6.36935,"twenty":-1.937182,"median":-0.851156,"eighty":-0.536619,"marketCap":142090478},{"date":"2020-06-05","current":-8.54727,"twenty":-2.211389,"median":-0.854597,"eighty":-0.538199,"marketCap":190676543},{"date":"2020-06-12","current":-8.524658,"twenty":-2.245297,"median":-0.858043,"eighty":-0.538857,"marketCap":190172108},{"date":"2020-06-19","current":-8.366375,"twenty":-2.282153,"median":-0.861395,"eighty":-0.539667,"marketCap":186641061},{"date":"2020-06-26","current":-11.984267,"twenty":-2.31901,"median":-0.864935,"eighty":-0.540746,"marketCap":267350709},{"date":"2020-07-02","current":-11.780761,"twenty":-2.329329,"median":-0.871046,"eighty":-0.542905,"marketCap":262810791},{"date":"2020-07-10","current":-25.268714,"twenty":-2.37798,"median":-0.876338,"eighty":-0.546142,"marketCap":563706447},{"date":"2020-07-17","current":-39.87374,"twenty":-2.464961,"median":-0.882047,"eighty":-0.551269,"marketCap":889522282},{"date":"2020-07-24","current":-35.658198,"twenty":-2.511587,"median":-0.882106,"eighty":-0.555317,"marketCap":795479975},{"date":"2020-07-31","current":-36.979902,"twenty":-2.577308,"median":-0.889057,"eighty":-0.558825,"marketCap":824965187},{"date":"2020-08-07","current":-38.092917,"twenty":-2.657548,"median":-0.893652,"eighty":-0.56016,"marketCap":849794839},{"date":"2020-08-14","current":-22.525667,"twenty":-2.805189,"median":-0.898031,"eighty":-0.561197,"marketCap":803907295},{"date":"2020-08-21","current":-21.96438,"twenty":-2.869381,"median":-0.902327,"eighty":-0.561253,"marketCap":783875813},{"date":"2020-08-28","current":-16.098684,"twenty":-2.956041,"median":-0.905258,"eighty":-0.561524,"marketCap":574537930},{"date":"2020-09-04","current":-11.35679,"twenty":-3.087213,"median":-0.907254,"eighty":-0.563087,"marketCap":405306837},{"date":"2020-09-11","current":-11.046146,"twenty":-3.177503,"median":-0.908968,"eighty":-0.565026,"marketCap":394220407},{"date":"2020-09-18","current":-12.900875,"twenty":-3.305887,"median":-0.909901,"eighty":-0.568591,"marketCap":460412915},{"date":"2020-09-25","current":-11.804484,"twenty":-3.450319,"median":-0.915777,"eighty":-0.568832,"marketCap":421284339},{"date":"2020-10-02","current":-11.850167,"twenty":-3.626847,"median":-0.919185,"eighty":-0.56887,"marketCap":422914696},{"date":"2020-10-09","current":-11.301971,"twenty":-4.67722,"median":-0.919185,"eighty":-0.570264,"marketCap":403350408},{"date":"2020-10-16","current":-11.850167,"twenty":-4.848628,"median":-0.928329,"eighty":-0.572047,"marketCap":422914696},{"date":"2020-10-23","current":-10.963917,"twenty":-5.046072,"median":-0.930791,"eighty":-0.572259,"marketCap":391285764},{"date":"2020-10-30","current":-10.461404,"twenty":-5.241612,"median":-0.937755,"eighty":-0.572714,"marketCap":373351833},{"date":"2020-11-06","current":-11.375064,"twenty":-5.335212,"median":-0.937755,"eighty":-0.576558,"marketCap":405958980},{"date":"2020-11-13","current":-7.837321,"twenty":-5.405412,"median":-0.941735,"eighty":-0.580401,"marketCap":333237614},{"date":"2020-11-20","current":-7.210645,"twenty":-5.429046,"median":-0.942397,"eighty":-0.581491,"marketCap":306591763},{"date":"2020-11-27","current":-8.139054,"twenty":-5.509728,"median":-0.943742,"eighty":-0.583694,"marketCap":346067098},{"date":"2020-12-04","current":-9.539405,"twenty":-5.616013,"median":-0.94704,"eighty":-0.584245,"marketCap":405609060},{"date":"2020-12-11","current":-9.260882,"twenty":-5.690893,"median":-0.956324,"eighty":-0.58732,"marketCap":393766460},{"date":"2020-12-18","current":-9.647719,"twenty":-5.791553,"median":-0.957434,"eighty":-0.588089,"marketCap":410214516},{"date":"2020-12-24","current":-8.858572,"twenty":-5.840973,"median":-0.958492,"eighty":-0.589596,"marketCap":376660482},{"date":"2020-12-31","current":-9.807293,"twenty":-5.850013,"median":-0.965609,"eighty":-0.590601,"marketCap":416999468},{"date":"2021-01-08","current":-12.276505,"twenty":-5.920213,"median":-0.96954,"eighty":-0.591133,"marketCap":521988696},{"date":"2021-01-15","current":-11.24187,"twenty":-6.051347,"median":-0.974894,"eighty":-0.591932,"marketCap":477996731},{"date":"2021-01-22","current":-12.476476,"twenty":-6.084014,"median":-0.976283,"eighty":-0.592399,"marketCap":530491345},{"date":"2021-01-29","current":-12.415615,"twenty":-6.19479,"median":-0.981857,"eighty":-0.595339,"marketCap":527903582},{"date":"2021-02-05","current":-15.962934,"twenty":-6.336734,"median":-0.985303,"eighty":-0.59962,"marketCap":678733177},{"date":"2021-02-12","current":-19.318976,"twenty":-7.087016,"median":-0.988821,"eighty":-0.59962,"marketCap":821429804},{"date":"2021-02-19","current":-19.936279,"twenty":-7.210645,"median":-0.990004,"eighty":-0.59962,"marketCap":847677111},{"date":"2021-02-26","current":-12.019122,"twenty":-7.357643,"median":-0.992005,"eighty":-0.59962,"marketCap":589471561},{"date":"2021-03-05","current":-9.757054,"twenty":-7.837321,"median":-0.998372,"eighty":-0.603077,"marketCap":478529611},{"date":"2021-03-12","current":-12.637421,"twenty":-8.231895,"median":-1.002367,"eighty":-0.603464,"marketCap":619795694},{"date":"2021-03-19","current":-12.381053,"twenty":-8.510418,"median":-1.005411,"eighty":-0.603464,"marketCap":607222273},{"date":"2021-03-26","current":-10.443215,"twenty":-8.587786,"median":-1.00739,"eighty":-0.605274,"marketCap":512182002},{"date":"2021-04-01","current":-10.556318,"twenty":-8.78138,"median":-1.016675,"eighty":-0.605274,"marketCap":517729100},{"date":"2021-04-09","current":-9.726893,"twenty":-9.292271,"median":-1.021158,"eighty":-0.6069,"marketCap":477050385},{"date":"2021-04-16","current":-9.251859,"twenty":-9.464501,"median":-1.024724,"eighty":-0.607307,"marketCap":453752575},{"date":"2021-04-23","current":-9.380043,"twenty":-9.464501,"median":-1.029527,"eighty":-0.607307,"marketCap":460039286},{"date":"2021-04-30","current":-10.910709,"twenty":-9.499174,"median":-1.032222,"eighty":-0.607307,"marketCap":535110005},{"date":"2021-05-07","current":-10.005881,"twenty":-9.568548,"median":-1.035738,"eighty":-0.608615,"marketCap":490733225},{"date":"2021-05-14","current":-10.088824,"twenty":-9.690182,"median":-1.043356,"eighty":-0.610709,"marketCap":494801097},{"date":"2021-05-21","current":-8.930849,"twenty":-9.656014,"median":-1.045001,"eighty":-0.612319,"marketCap":536054794},{"date":"2021-05-28","current":-8.0639,"twenty":-9.614543,"median":-1.047082,"eighty":-0.613503,"marketCap":484018069},{"date":"2021-06-04","current":-8.255139,"twenty":-9.601725,"median":-1.054534,"eighty":-0.614487,"marketCap":495496759},{"date":"2021-06-11","current":-9.160335,"twenty":-9.601725,"median":-1.060147,"eighty":-0.617301,"marketCap":549829222},{"date":"2021-06-18","current":-10.18665,"twenty":-9.645972,"median":-1.061987,"eighty":-0.619095,"marketCap":611431522},{"date":"2021-06-25","current":-10.250396,"twenty":-9.735941,"median":-1.064048,"eighty":-0.619675,"marketCap":615257751},{"date":"2021-07-02","current":-5.953899,"twenty":-9.75253,"median":-1.073166,"eighty":-0.622777,"marketCap":357369863},{"date":"2021-07-09","current":-5.871029,"twenty":-9.740466,"median":-1.078488,"eighty":-0.625409,"marketCap":352395764},{"date":"2021-07-16","current":-5.603295,"twenty":-9.713792,"median":-1.081387,"eighty":-0.626526,"marketCap":336325599},{"date":"2021-07-23","current":-5.660666,"twenty":-9.692161,"median":-1.084345,"eighty":-0.626829,"marketCap":339769206},{"date":"2021-07-30","current":-5.781784,"twenty":-9.672603,"median":-1.09804,"eighty":-0.627284,"marketCap":347039042},{"date":"2021-08-06","current":-6.53399,"twenty":-9.646554,"median":-1.106702,"eighty":-0.627284,"marketCap":392188554},{"date":"2021-08-13","current":-6.989861,"twenty":-9.629384,"median":-1.114155,"eighty":-0.627315,"marketCap":475890082},{"date":"2021-08-20","current":-7.373664,"twenty":-9.603233,"median":-1.117881,"eighty":-0.628565,"marketCap":502020486},{"date":"2021-08-27","current":-8.542517,"twenty":-9.583629,"median":-1.12906,"eighty":-0.630603,"marketCap":581599443},{"date":"2021-09-03","current":-9.554361,"twenty":-9.558349,"median":-1.132786,"eighty":-0.630952,"marketCap":650488690},{"date":"2021-09-10","current":-9.775338,"twenty":-9.591169,"median":-1.136512,"eighty":-0.630952,"marketCap":665533468},{"date":"2021-09-17","current":-8.862353,"twenty":-9.605176,"median":-1.137989,"eighty":-0.631686,"marketCap":603374780},{"date":"2021-09-24","current":-8.705343,"twenty":-9.600447,"median":-1.155144,"eighty":-0.635355,"marketCap":592685069},{"date":"2021-10-01","current":-6.949155,"twenty":-9.591169,"median":-1.16462,"eighty":-0.638289,"marketCap":473118675},{"date":"2021-10-08","current":-7.077089,"twenty":-9.559679,"median":-1.173775,"eighty":-0.638289,"marketCap":481828810},{"date":"2021-10-15","current":-6.984046,"twenty":-9.554182,"median":-1.181272,"eighty":-0.638815,"marketCap":475494167},{"date":"2021-10-22","current":-6.699101,"twenty":-9.550655,"median":-1.192207,"eighty":-0.641115,"marketCap":456094321},{"date":"2021-10-29","current":-6.280407,"twenty":-9.538907,"median":-1.192406,"eighty":-0.641912,"marketCap":427588426},{"date":"2021-11-05","current":-6.303668,"twenty":-9.536915,"median":-1.195875,"eighty":-0.642691,"marketCap":429172087},{"date":"2021-11-12","current":-5.254536,"twenty":-9.534318,"median":-1.207066,"eighty":-0.645626,"marketCap":440449772},{"date":"2021-11-19","current":-4.989681,"twenty":-9.517742,"median":-1.21849,"eighty":-0.645626,"marketCap":418248884},{"date":"2021-11-26","current":-4.928196,"twenty":-9.492985,"median":-1.222217,"eighty":-0.645626,"marketCap":413095106},{"date":"2021-12-03","current":-4.483618,"twenty":-9.492985,"median":-1.234811,"eighty":-0.645626,"marketCap":375829329},{"date":"2021-12-10","current":-4.455241,"twenty":-9.478066,"median":-1.237122,"eighty":-0.645626,"marketCap":373450662},{"date":"2021-12-17","current":-4.426864,"twenty":-9.474354,"median":-1.242711,"eighty":-0.645626,"marketCap":371071995},{"date":"2021-12-23","current":-4.351191,"twenty":-9.464501,"median":-1.250163,"eighty":-0.64856,"marketCap":364728884},{"date":"2021-12-31","current":-4.332272,"twenty":-9.444757,"median":-1.266932,"eighty":-0.649294,"marketCap":363143107},{"date":"2022-01-07","current":-3.916072,"twenty":-9.429228,"median":-1.270658,"eighty":-0.649294,"marketCap":328255996},{"date":"2022-01-14","current":-3.707971,"twenty":-9.419545,"median":-1.300468,"eighty":-0.649294,"marketCap":310812440},{"date":"2022-01-21","current":-3.305959,"twenty":-9.395156,"median":-1.357281,"eighty":-0.649294,"marketCap":277114663},{"date":"2022-01-28","current":-3.40528,"twenty":-9.375518,"median":-1.896273,"eighty":-0.649294,"marketCap":285439996},{"date":"2022-02-04","current":-3.622839,"twenty":-9.356009,"median":-2.181903,"eighty":-0.649294,"marketCap":303676441},{"date":"2022-02-11","current":-3.632298,"twenty":-9.294535,"median":-2.226131,"eighty":-0.651495,"marketCap":304469329},{"date":"2022-02-18","current":-3.339066,"twenty":-9.255468,"median":-2.240874,"eighty":-0.652962,"marketCap":279889774},{"date":"2022-02-25","current":-3.599191,"twenty":-9.25041,"median":-2.262988,"eighty":-0.65443,"marketCap":301694218},{"date":"2022-03-04","current":-3.277582,"twenty":-9.216158,"median":-2.281416,"eighty":-0.656631,"marketCap":274735996},{"date":"2022-03-11","current":-3.29177,"twenty":-9.164959,"median":-2.299844,"eighty":-0.656631,"marketCap":275925330},{"date":"2022-03-18","current":-3.187041,"twenty":-9.152685,"median":-2.321958,"eighty":-0.656631,"marketCap":309429796},{"date":"2022-03-25","current":-2.824576,"twenty":-9.120812,"median":-2.329329,"eighty":-0.656889,"marketCap":274238058},{"date":"2022-04-01","current":-2.749431,"twenty":-9.069815,"median":-2.351443,"eighty":-0.658485,"marketCap":266942209},{"date":"2022-04-08","current":-2.510734,"twenty":-9.026468,"median":-2.395671,"eighty":-0.660299,"marketCap":243767162},{"date":"2022-04-14","current":-2.31182,"twenty":-9.002244,"median":-2.403042,"eighty":-0.660299,"marketCap":224454623},{"date":"2022-04-22","current":-2.006819,"twenty":-8.981208,"median":-2.373557,"eighty":-0.660299,"marketCap":194842063},{"date":"2022-04-29","current":-1.997978,"twenty":-8.97802,"median":-2.3367,"eighty":-0.660463,"marketCap":193983728},{"date":"2022-05-06","current":-1.913993,"twenty":-8.974196,"median":-2.325643,"eighty":-0.661689,"marketCap":185829544},{"date":"2022-05-13","current":-2.19104,"twenty":-8.962867,"median":-2.314587,"eighty":-0.663967,"marketCap":222734186},{"date":"2022-05-20","current":-2.131593,"twenty":-8.93653,"median":-2.296159,"eighty":-0.664701,"marketCap":216691010},{"date":"2022-05-27","current":-2.13584,"twenty":-8.925681,"median":-2.280878,"eighty":-0.66787,"marketCap":217122666},{"date":"2022-06-03","current":-2.309934,"twenty":-8.905008,"median":-2.27773,"eighty":-0.668807,"marketCap":234820537},{"date":"2022-06-10","current":-3.630503,"twenty":-8.886226,"median":-2.28299,"eighty":-0.668883,"marketCap":369065367},{"date":"2022-06-17","current":-3.830074,"twenty":-8.882388,"median":-2.299844,"eighty":-0.671304,"marketCap":389353170},{"date":"2022-06-24","current":-4.369342,"twenty":-8.86636,"median":-2.31182,"eighty":-0.671304,"marketCap":444173406},{"date":"2022-07-01","current":-4.781223,"twenty":-8.859328,"median":-2.321958,"eighty":-0.671304,"marketCap":486043980},{"date":"2022-07-08","current":-5.379938,"twenty":-8.843395,"median":-2.329329,"eighty":-0.672112,"marketCap":546907391},{"date":"2022-07-15","current":-4.810947,"twenty":-8.833277,"median":-2.3367,"eighty":-0.673733,"marketCap":489065568},{"date":"2022-07-22","current":-5.554032,"twenty":-8.79056,"median":-2.3883,"eighty":-0.674765,"marketCap":564605263},{"date":"2022-07-29","current":-5.099688,"twenty":-8.752462,"median":-2.431168,"eighty":-0.674972,"marketCap":518418135},{"date":"2022-08-05","current":-5.26529,"twenty":-8.743932,"median":-2.458327,"eighty":-0.677129,"marketCap":535252696},{"date":"2022-08-12","current":-8.685942,"twenty":-8.727192,"median":-2.479782,"eighty":-0.678611,"marketCap":841987671},{"date":"2022-08-19","current":-8.585874,"twenty":-8.767651,"median":-2.479782,"eighty":-0.678611,"marketCap":832287353},{"date":"2022-08-26","current":-9.231316,"twenty":-8.857064,"median":-2.479782,"eighty":-0.678611,"marketCap":894854409},{"date":"2022-09-02","current":-11.212671,"twenty":-8.915344,"median":-2.479782,"eighty":-0.678611,"marketCap":1086920721},{"date":"2022-09-09","current":-9.996839,"twenty":-8.976745,"median":-2.479782,"eighty":-0.678611,"marketCap":969061848},{"date":"2022-09-16","current":-6.839679,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":663016789},{"date":"2022-09-23","current":-6.189234,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":599964717},{"date":"2022-09-30","current":-6.453807,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":625611519},{"date":"2022-10-07","current":-5.28636,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":512442952},{"date":"2022-10-14","current":-5.256037,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":509503508},{"date":"2022-10-21","current":-5.422815,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":525670447},{"date":"2022-10-28","current":-6.453807,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":625611519},{"date":"2022-11-04","current":-5.983796,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":580050148},{"date":"2022-11-11","current":-6.042666,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":525366485},{"date":"2022-11-18","current":-4.996929,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":434447121},{"date":"2022-11-25","current":-5.138245,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":446733522},{"date":"2022-12-02","current":-6.376172,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":554362390},{"date":"2022-12-09","current":-5.709161,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":496370580},{"date":"2022-12-16","current":-6.489225,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":564191510},{"date":"2022-12-23","current":-8.665489,"twenty":-8.992045,"median":-2.479782,"eighty":-0.678611,"marketCap":753402078},{"date":"2022-12-30","current":-9.298584,"twenty":-9.046009,"median":-2.479782,"eighty":-0.678611,"marketCap":808445152},{"date":"2023-01-06","current":-8.077615,"twenty":-9.046009,"median":-2.550468,"eighty":-0.678611,"marketCap":702290652},{"date":"2023-01-13","current":-9.208142,"twenty":-9.082964,"median":-2.674285,"eighty":-0.678611,"marketCap":800581856},{"date":"2023-01-20","current":-8.111531,"twenty":-9.082964,"median":-2.74501,"eighty":-0.678611,"marketCap":705239388},{"date":"2023-01-27","current":-7.478436,"twenty":-9.082964,"median":-2.834635,"eighty":-0.678611,"marketCap":650196314},{"date":"2023-02-03","current":-8.569394,"twenty":-9.082964,"median":-3.041104,"eighty":-0.682837,"marketCap":745047326},{"date":"2023-02-10","current":-7.591488,"twenty":-9.082964,"median":-3.089794,"eighty":-0.692599,"marketCap":660025434},{"date":"2023-02-17","current":-6.760551,"twenty":-9.082964,"median":-3.29177,"eighty":-0.706713,"marketCap":587781399},{"date":"2023-02-24","current":-6.771856,"twenty":-9.082964,"median":-3.329607,"eighty":-0.719867,"marketCap":588764311},{"date":"2023-03-03","current":-6.742082,"twenty":-9.082964,"median":-3.358746,"eighty":-0.742102,"marketCap":571141998},{"date":"2023-03-10","current":-6.032389,"twenty":-9.082964,"median":-3.414739,"eighty":-0.768114,"marketCap":511021788},{"date":"2023-03-17","current":-6.404687,"twenty":-9.082964,"median":-3.495141,"eighty":-0.78253,"marketCap":542560259},{"date":"2023-03-24","current":-2.513011,"twenty":-9.082964,"median":-3.5046,"eighty":-0.796016,"marketCap":212884679},{"date":"2023-03-31","current":-2.454839,"twenty":-9.080548,"median":-3.499871,"eighty":-0.802556,"marketCap":207956793},{"date":"2023-04-06","current":-2.251239,"twenty":-9.080548,"median":-3.499871,"eighty":-0.804482,"marketCap":190709192},{"date":"2023-04-14","current":-2.681708,"twenty":-9.082964,"median":-3.5046,"eighty":-0.809804,"marketCap":227175549},{"date":"2023-04-21","current":-3.33323,"twenty":-9.082964,"median":-3.5046,"eighty":-0.816048,"marketCap":282367873},{"date":"2023-04-28","current":-2.885309,"twenty":-9.085381,"median":-3.51872,"eighty":-0.82152,"marketCap":244423150},{"date":"2023-05-05","current":-2.873674,"twenty":-9.085381,"median":-3.51872,"eighty":-0.831857,"marketCap":243437573},{"date":"2023-05-12","current":-3.100543,"twenty":-9.085381,"median":-3.51872,"eighty":-0.840814,"marketCap":262656329},{"date":"2023-05-19","current":-2.569103,"twenty":-9.085381,"median":-3.51872,"eighty":-0.844264,"marketCap":219290931},{"date":"2023-05-26","current":-2.431202,"twenty":-9.085381,"median":-3.51872,"eighty":-0.854355,"marketCap":207520115},{"date":"2023-06-02","current":-2.396553,"twenty":-9.085381,"median":-3.51872,"eighty":-0.858045,"marketCap":204562584},{"date":"2023-06-09","current":-2.361904,"twenty":-9.085381,"median":-3.51872,"eighty":-0.86619,"marketCap":201605053},{"date":"2023-06-16","current":-2.361904,"twenty":-9.085381,"median":-3.51872,"eighty":-0.879261,"marketCap":201605053},{"date":"2023-06-23","current":-2.402328,"twenty":-9.087797,"median":-3.53284,"eighty":-0.88307,"marketCap":205055506},{"date":"2023-06-30","current":-2.021189,"twenty":-9.090214,"median":-3.532909,"eighty":-0.895974,"marketCap":172522661},{"date":"2023-07-07","current":-1.940342,"twenty":-9.090214,"median":-3.532909,"eighty":-0.899395,"marketCap":165621755},{"date":"2023-07-14","current":-1.957666,"twenty":-9.090214,"median":-3.532909,"eighty":-0.906287,"marketCap":167100520},{"date":"2023-07-21","current":-1.836395,"twenty":-9.090214,"median":-3.532909,"eighty":-0.909901,"marketCap":156749161},{"date":"2023-07-28","current":-1.726673,"twenty":-9.090214,"median":-3.532909,"eighty":-0.919185,"marketCap":147383645},{"date":"2023-08-04","current":-1.795971,"twenty":-9.090214,"median":-3.532909,"eighty":-0.928329,"marketCap":153298707},{"date":"2023-08-11","current":-1.969804,"twenty":-9.090214,"median":-3.532909,"eighty":-0.937755,"marketCap":160166735},{"date":"2023-08-18","current":-1.743017,"twenty":-9.090214,"median":-3.532909,"eighty":-0.941735,"marketCap":141726485},{"date":"2023-08-25","current":-1.587507,"twenty":-9.090214,"median":-3.532909,"eighty":-0.945086,"marketCap":129081743},{"date":"2023-09-01","current":-1.639343,"twenty":-9.090214,"median":-3.532909,"eighty":-0.956324,"marketCap":133296657},{"date":"2023-09-08","current":-1.593986,"twenty":-9.090214,"median":-3.532909,"eighty":-0.958492,"marketCap":129608607},{"date":"2023-09-15","current":-1.807814,"twenty":-9.090214,"median":-3.532909,"eighty":-0.970251,"marketCap":146995128},{"date":"2023-09-22","current":-1.658782,"twenty":-9.090214,"median":-3.532909,"eighty":-0.979536,"marketCap":134877250},{"date":"2023-09-29","current":-1.619905,"twenty":-9.090214,"median":-3.532909,"eighty":-0.985303,"marketCap":131716065},{"date":"2023-10-06","current":-1.684701,"twenty":-9.090214,"median":-3.532909,"eighty":-0.991188,"marketCap":136984707},{"date":"2023-10-13","current":-1.69118,"twenty":-9.090214,"median":-3.532909,"eighty":-1.00206,"marketCap":137511571},{"date":"2023-10-20","current":-1.509751,"twenty":-9.090214,"median":-3.532909,"eighty":-1.006093,"marketCap":122759372},{"date":"2023-10-27","current":-1.503271,"twenty":-9.120812,"median":-3.537707,"eighty":-1.019689,"marketCap":122232508},{"date":"2023-11-03","current":-1.658782,"twenty":-9.120812,"median":-3.537707,"eighty":-1.028451,"marketCap":134877250},{"date":"2023-11-10","current":-1.677615,"twenty":-9.120812,"median":-3.537707,"eighty":-1.034911,"marketCap":131635733},{"date":"2023-11-17","current":-1.615988,"twenty":-9.120812,"median":-3.537707,"eighty":-1.035705,"marketCap":126800135},{"date":"2023-11-24","current":-1.924122,"twenty":-9.120812,"median":-3.537707,"eighty":-1.035705,"marketCap":150978127},{"date":"2023-12-01","current":-2.163781,"twenty":-9.120812,"median":-3.537707,"eighty":-1.035705,"marketCap":169783232},{"date":"2023-12-08","current":-4.505594,"twenty":-9.110613,"median":-3.544802,"eighty":-1.035771,"marketCap":353535971},{"date":"2023-12-15","current":-4.793186,"twenty":-9.110613,"median":-3.60865,"eighty":-1.041865,"marketCap":376102097},{"date":"2023-12-22","current":-5.402605,"twenty":-9.110613,"median":-3.686688,"eighty":-1.046438,"marketCap":423920792},{"date":"2023-12-29","current":-7.956688,"twenty":-9.120812,"median":-3.745808,"eighty":-1.059015,"marketCap":624329481},{"date":"2024-01-05","current":-8.00462,"twenty":-9.131012,"median":-3.795468,"eighty":-1.062066,"marketCap":628090501},{"date":"2024-01-12","current":-7.867672,"twenty":-9.131012,"median":-3.884844,"eighty":-1.073911,"marketCap":617344727},{"date":"2024-01-19","current":-7.388353,"twenty":-9.141211,"median":-4.008415,"eighty":-1.078488,"marketCap":579734518},{"date":"2024-01-26","current":-6.354395,"twenty":-9.131012,"median":-4.119442,"eighty":-1.078619,"marketCap":498603922},{"date":"2024-02-02","current":-6.765239,"twenty":-9.131012,"median":-4.20221,"eighty":-1.078619,"marketCap":530841245},{"date":"2024-02-09","current":-6.635138,"twenty":-9.131012,"median":-4.339366,"eighty":-1.078619,"marketCap":520632759},{"date":"2024-02-16","current":-6.12843,"twenty":-9.131012,"median":-4.37682,"eighty":-1.078619,"marketCap":480873395},{"date":"2024-02-23","current":-6.073651,"twenty":-9.131012,"median":-4.459875,"eighty":-1.082595,"marketCap":476575085},{"date":"2024-03-01","current":-8.285364,"twenty":-9.152685,"median":-4.505594,"eighty":-1.101931,"marketCap":650119339},{"date":"2024-03-08","current":-6.86795,"twenty":-9.152685,"median":-4.658612,"eighty":-1.122353,"marketCap":538900576},{"date":"2024-03-15","current":-6.864526,"twenty":-9.152685,"median":-4.78631,"eighty":-1.163594,"marketCap":538631931},{"date":"2024-03-22","current":-6.237989,"twenty":-9.152685,"median":-4.819439,"eighty":-1.201744,"marketCap":489470014},{"date":"2024-03-28","current":-7.125839,"twenty":-9.152685,"median":-4.887378,"eighty":-1.371955,"marketCap":630259092},{"date":"2024-04-05","current":-7.133855,"twenty":-9.15651,"median":-4.944847,"eighty":-1.549925,"marketCap":630968045},{"date":"2024-04-12","current":-6.733076,"twenty":-9.15651,"median":-4.976853,"eighty":-1.582323,"marketCap":595520402},{"date":"2024-04-19","current":-5.522726,"twenty":-9.15651,"median":-5.010669,"eighty":-1.603058,"marketCap":488468520},{"date":"2024-04-26","current":-5.771208,"twenty":-9.152685,"median":-5.065719,"eighty":-1.622497,"marketCap":510446059},{"date":"2024-05-03","current":-5.763193,"twenty":-9.152685,"median":-5.137904,"eighty":-1.632864,"marketCap":509737106},{"date":"2024-05-10","current":-5.900173,"twenty":-9.152685,"median":-5.17612,"eighty":-1.651056,"marketCap":547341314},{"date":"2024-05-17","current":-6.802306,"twenty":-9.152685,"median":-5.23434,"eighty":-1.663576,"marketCap":631029499},{"date":"2024-05-24","current":-5.648207,"twenty":-9.152685,"median":-5.250196,"eighty":-1.680449,"marketCap":523967191},{"date":"2024-05-31","current":-5.365414,"twenty":-9.152685,"median":-5.252552,"eighty":-1.69118,"marketCap":497733380},{"date":"2024-06-07","current":-5.143766,"twenty":-9.152685,"median":-5.262603,"eighty":-1.719691,"marketCap":477171745},{"date":"2024-06-14","current":-5.05205,"twenty":-9.15651,"median":-5.263947,"eighty":-1.733603,"marketCap":468663482},{"date":"2024-06-21","current":-4.539966,"twenty":-9.160335,"median":-5.26529,"eighty":-1.749497,"marketCap":421159014},{"date":"2024-06-28","current":-4.880081,"twenty":-9.164959,"median":-5.282272,"eighty":-1.761776,"marketCap":452710489},{"date":"2024-07-05","current":-5.044407,"twenty":-9.164959,"median":-5.287002,"eighty":-1.782905,"marketCap":467954460},{"date":"2024-07-12","current":-5.869855,"twenty":-9.164959,"median":-5.307752,"eighty":-1.813296,"marketCap":544528826},{"date":"2024-07-15","current":-6.038002,"twenty":-9.164959,"median":-5.325968,"eighty":-1.814927,"marketCap":560127308},{"date":"2024-08-02","current":-4.654611,"twenty":-9.22331,"median":-5.382384,"eighty":-1.858355,"marketCap":431794343},{"date":"2024-08-09","current":-4.4375,"twenty":-9.22331,"median":-5.382384,"eighty":-1.898763,"marketCap":449722870},{"date":"2024-08-16","current":-4.375927,"twenty":-9.22331,"median":-5.382384,"eighty":-1.922746,"marketCap":443482734},{"date":"2024-08-23","current":-4.740588,"twenty":-9.22331,"median":-5.382384,"eighty":-1.94836,"marketCap":480439628},{"date":"2024-08-30","current":-4.635397,"twenty":-9.22331,"median":-5.382384,"eighty":-1.963276,"marketCap":469778986},{"date":"2024-09-06","current":-4.481118,"twenty":-9.22331,"median":-5.382384,"eighty":-1.992315,"marketCap":454143376},{"date":"2024-09-13","current":-4.97902,"twenty":-9.22331,"median":-5.382384,"eighty":-2.006297,"marketCap":504603752},{"date":"2024-09-20","current":-5.308617,"twenty":-9.22331,"median":-5.392613,"eighty":-2.04582,"marketCap":538007099},{"date":"2024-09-27","current":-4.775651,"twenty":-9.22331,"median":-5.402605,"eighty":-2.071356,"marketCap":483993176},{"date":"2024-10-04","current":-4.312813,"twenty":-9.22331,"median":-5.402605,"eighty":-2.098777,"marketCap":437086348},{"date":"2024-10-11","current":-4.221648,"twenty":-9.22331,"median":-5.402605,"eighty":-2.13584,"marketCap":427847125},{"date":"2024-10-18","current":-4.761626,"twenty":-9.22331,"median":-5.402605,"eighty":-2.165516,"marketCap":482571757},{"date":"2024-10-25","current":-4.744094,"twenty":-9.22331,"median":-5.402605,"eighty":-2.226131,"marketCap":480794983},{"date":"2024-10-31","current":-4.740588,"twenty":-9.22331,"median":-5.402605,"eighty":-2.244588,"marketCap":480439628},{"date":"2024-11-08","current":-5.231477,"twenty":-9.225312,"median":-5.405129,"eighty":-2.271833,"marketCap":530189294},{"date":"2024-11-15","current":-5.809106,"twenty":-9.225312,"median":-5.445898,"eighty":-2.292553,"marketCap":601358704},{"date":"2024-11-22","current":-5.774753,"twenty":-9.225312,"median":-5.463564,"eighty":-2.309931,"marketCap":597802473},{"date":"2024-11-29","current":-5.888119,"twenty":-9.225312,"median":-5.498958,"eighty":-2.31901,"marketCap":609538036},{"date":"2024-12-06","current":-6.279744,"twenty":-9.225312,"median":-5.534802,"eighty":-2.33289,"marketCap":650079072},{"date":"2024-12-13","current":-5.90186,"twenty":-9.225312,"median":-5.583452,"eighty":-2.353729,"marketCap":610960528},{"date":"2024-12-20","current":-5.620165,"twenty":-9.225312,"median":-5.617263,"eighty":-2.367082,"marketCap":581799432},{"date":"2024-12-27","current":-5.496493,"twenty":-9.225312,"median":-5.622268,"eighty":-2.3962,"marketCap":568997000},{"date":"2025-01-03","current":-4.885009,"twenty":-9.225312,"median":-5.622268,"eighty":-2.406198,"marketCap":505696083},{"date":"2025-01-10","current":-5.11861,"twenty":-9.227313,"median":-5.624371,"eighty":-2.432957,"marketCap":529878456},{"date":"2025-01-17","current":-4.610184,"twenty":-9.227313,"median":-5.624371,"eighty":-2.450298,"marketCap":477246233},{"date":"2025-01-24","current":-4.850655,"twenty":-9.227313,"median":-5.624371,"eighty":-2.462386,"marketCap":502139852},{"date":"2025-01-31","current":-4.809432,"twenty":-9.227313,"median":-5.624371,"eighty":-2.492163,"marketCap":497872375},{"date":"2025-02-07","current":-4.747596,"twenty":-9.227313,"median":-5.624371,"eighty":-2.545445,"marketCap":491471158},{"date":"2025-02-14","current":-4.280394,"twenty":-9.227313,"median":-5.624371,"eighty":-2.577061,"marketCap":443106413},{"date":"2025-02-21","current":-4.555219,"twenty":-9.227313,"median":-5.624371,"eighty":-2.609749,"marketCap":471556263},{"date":"2025-02-28","current":-4.886485,"twenty":-9.227313,"median":-5.624371,"eighty":-2.682852,"marketCap":464504340},{"date":"2025-03-07","current":-4.528833,"twenty":-9.229315,"median":-5.62647,"eighty":-2.751011,"marketCap":430506348},{"date":"2025-03-14","current":-4.212868,"twenty":-9.229315,"median":-5.62647,"eighty":-2.800801,"marketCap":400471021},{"date":"2025-03-21","current":-4.682765,"twenty":-9.229315,"median":-5.62647,"eighty":-2.864367,"marketCap":445138943},{"date":"2025-03-28","current":-4.51263,"twenty":-9.229315,"median":-5.62647,"eighty":-2.887636,"marketCap":428966075},{"date":"2025-04-04","current":-3.613344,"twenty":-9.229315,"median":-5.62647,"eighty":-2.950267,"marketCap":343480914},{"date":"2025-04-11","current":-3.370294,"twenty":-9.227313,"median":-5.624371,"eighty":-3.036633,"marketCap":320376817},{"date":"2025-04-17","current":-3.564734,"twenty":-9.227313,"median":-5.624371,"eighty":-3.077604,"marketCap":338860095},{"date":"2025-04-25","current":-4.188563,"twenty":-9.229315,"median":-5.62647,"eighty":-3.116395,"marketCap":398160611},{"date":"2025-05-02","current":-4.188563,"twenty":-9.229315,"median":-5.62647,"eighty":-3.213748,"marketCap":398160611},{"date":"2025-05-07","current":-4.07514,"twenty":-9.229315,"median":-5.62647,"eighty":-3.29177,"marketCap":387378699}],"updateTime":1746749326934}}}